化瘀止痛胶囊合敷脐止痛散配合治疗子宫腺肌病的临床研究

《化瘀止痛胶囊合敷脐止痛散配合治疗子宫腺肌病的临床研究》由会员上传分享，免费在线阅读，更多相关内容在学术论文-天天文库。

1、TheClinicalResearchontheEffectofHuaYuZhiTongCapsuleandFuQiZhiTongPowderinTreatingAdenomyosisSpeciality:GynecologyofTCM,ThestudyofmenstruationsicknessandsterilityTutor:ProfessorYeQingAuthor:ZhangJingAbstractObjective：ObservetheclinicalcurativeeffectofHuaYuZhiTongCapsu

2、lecombinedwithFuQiZhiTongPowder,whichisappliedtotreatadenomyosisdysmenorrheaandexploreitsworkmechanism.Methods:Wetotallyobserved65patientsofadenomyosisanditwasdividedintotwogroupsrandomly.ThetreatmentgrouptakeHuaYuZhiTongCapsulecombinedwithFuQiZhiTongPowder,whilethec

3、ontrolgrouptakesSanJieZhenTongcapsuleandHuaJi,whicharecomparedtoobservetheircurativeeffectsandimpactsonCA125、prostaglandinE2andtumornecrosisfactor-α.Results:Aftertreatment,thedysmenorrhealevelscoreofthetwogroupswereobviouslydecreased(P<0.05)buttherewerenosignificantd

4、ifferencesbetweengroups(P＞0.05).Thesyndromescoreofthetreatmentgrouphassignificantdifference(P<0.05orP<0.01)，whilemostlyofthecontrolgroupwasthesameasbefore.TheUterinevolume、CA125andprostaglandinE2ofthetreatmentgroupisobviouslydecreasedaftertreating,whichhassignificant

5、differencescomparedwithitsoriginallevel(P<0.05orP<0.01)andtheprostaglandinE2ofthecontrolgrouphassignificantdifferencescomparedwithitsoriginallevel(P<0.01).Thetumornecrosisfactor–αlevelofthetreatmentgroupisobviouslydecreasedaftertreating,whichhassignificantdifferences

6、comparedwithitsoriginallevel(P<0.01)andthecontrolgroup(P<0.01).Conclusion:HuaYuZhiTongCapsulecombinedwithFuQiZhiTongPowderhasbettereffectintreatingadenomyosis.Itnotonlycanalleviatethesymptomofmenstrualcolic,butalsocanregulatemenstrualdisorders,whiletheimprovementofth

7、elatteroneisparticularlyremarkable.Themechanismmayberelatedtoinhibitinvasionforceoftheectopicendometrium,reducedthegrowthofnewbloodvesselsinordertodecreasetheliningoftheplant,narrowtheuterinevolumeandlessenthequantityofmenstrual.KeywordsAdenomyosis；HuaYuZhiTongCapsul

8、e；FuQiZhiTongPowder；tumornecrosisfactor-α目录引言......................................................................................